预约演示
更新于：2026-02-25
Perindopril Arginine
精氨酸培哚普利
更新于：2026-02-25
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H46N6O7 |
InChIKeyRYCSJJXKEWBUTI-YDYAIEMNSA-N |
CAS号612548-45-5 |
关联
10
项与 精氨酸培哚普利 相关的临床试验CTR20240279
精氨酸培哚普利片在中国成年健康受试者中的生物等效性研究
CTR20233406
精氨酸培哚普利片人体生物等效性研究
CTR20230504
一项单中心、随机、开放、单次给药、两制剂、两周期交叉设计研究评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片在健康受试者中的空腹和餐后状态下的生物等效性研究
100 项与 精氨酸培哚普利 相关的临床结果
登录后查看更多信息
100 项与 精氨酸培哚普利 相关的转化医学
登录后查看更多信息
100 项与 精氨酸培哚普利 相关的专利（医药）
登录后查看更多信息
2,327
项与 精氨酸培哚普利 相关的文献（医药）2026-02-01Cardiovascular Toxicology
Role of Perindopril in Mitigating Doxorubicin’s Vascular Toxicity in a Rat Model
Article
作者: Šůstková, Lucie ; Hložková, Jana ; Nádeníček, Jaroslav ; Nováková, Marie ; Smutná, Jindra ; Studenik, Christian ; Marhefka, Filip ; Hendrych, Michal ; Scheer, Peter ; Stračina, Tibor ; Marada, Anna ; Paulová, Hana
Abstract:
Doxorubicin (DOX), a widely used anthracycline in cancer therapy, is associated with significant cardiovascular toxicity. While its cardiotoxic effects are well documented, the mechanisms and prevention of DOX-induced vascular toxicity remain insufficiently explored. Angiotensin-converting enzyme inhibitors (ACEIs), such as perindopril (PER), are commonly used in cardiovascular disease management and may offer vascular protection during chemotherapy. Female ovariectomized Wistar rats were treated with
i.v.
DOX and/or
p.o.
PER over five weeks. Cardiac and vascular function were assessed using high-frequency ultrasound and ECG. Vascular reactivity was evaluated in isolated aortal rings using phenylephrine (PE), acetylcholine (ACh), L-N-Nitro arginine methyl ester hydrochloride (L-NAME), and verapamil (VER). Oxidative stress was assessed via plasma 4-hydroxy-2-nonenal (4-HNE) levels, and structural changes were monitored through intima-media thickness (IMT) measurements. DOX administration significantly impaired vascular reactivity, as evidenced by increased contractile responses to PE and reduced endothelium-dependent relaxation. These functional alterations were accompanied by elevated plasma 4-HNE levels, indicating enhanced oxidative stress. Co-treatment with PER preserved vascular responsiveness, reduced contractile tension, and significantly lowered 4-HNE concentrations. Structurally, IMT increased in control and PER-only groups, likely due to post-ovariectomy remodelling, while DOX-treated groups showed no IMT progression. PER co-treatment appeared to stabilize IMT values. PER mitigates DOX-induced vascular toxicity, likely through endothelial protection and reduction of oxidative stress. These findings support the potential use of ACEIs as prophylactic agents in patients undergoing anthracycline-based chemotherapy and highlight the need for further translational studies in cardio-oncology.
Graphical Abstract
2026-02-01PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Effectiveness of Indapamide Prolonged‐Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation
Article
作者: Jacquot, Emmanuelle ; Garcia‐Albeniz, Xabier ; Mangin, Marie ; Simon, Virginie ; Ballon, Morgane ; Aguado, Jaume ; Darricarrere, Céline ; Pladevall‐Vila, Manel ; Procureur, Dominique
ABSTRACT:
Objective:
To assess the effectiveness of indapamide prolonged release and perindopril in combination using blood pressure (BP) records collected in routine practice.
Methods:
Using a target trial emulation framework, an observational retrospective cohort study was conducted. The data source was the United Kingdom's CPRD Aurum general practice database. Adults with systolic BP (SBP) ≥ 145 mmHg treated with perindopril 4/5 mg for ≥ 4 weeks at a stable dose who either added indapamide 1.5 mg to perindopril (
n
= 193) or continued on perindopril monotherapy (
n
= 14 571) were included. Balance between treatment arms was achieved with propensity score matching; results were explored in additional analyses using different eligibility criteria and alternative statistical methodologies. The primary outcome was change in SBP from baseline to Week 8 between indapamide added to perindopril versus perindopril monotherapy.
Results:
In the primary analysis, indapamide added to perindopril yielded an additional SBP reduction of −6.3 mmHg (95% confidence interval [CI] −8.7 to −3.9) over perindopril monotherapy at Week 8. Results of additional analyses were consistent with the main analysis, but effect estimates varied due to diverse underlying assumptions.
Conclusions:
Target trial emulation allowed assessment of antihypertensive treatment effectiveness, and indapamide plus perindopril yielded clinically meaningful decreases in SBP over perindopril monotherapy. Secondary and sensitivity analyses support that these findings were robust.
2026-01-01Profiles of drug substances, excipients, and related methodology
Perindopril: A comprehensive profile
Review
作者: Azzazy, Hassan Mohamed El-Said ; Lababidi, Jude Majed ; Kabil, Mohamed Fawzy
Perindopril (PER) is classified as angiotensin-converting enzyme (ACE) inhibitors and is used primarily for the management of hypertension and cardiovascular conditions, including heart failure and stable coronary artery disease. Two primary salts of PER have been developed, perindopril arginine (PER-Arg) and perindopril erbumine (PER-E). This chapter presents a detailed overview on the physicochemical attributes of PER-Arg, molecular structure, synthetic pathway, crystallographic behavior, thermal stability, and UV absorbance profile of PER-Arg. Moreover, the chromatographic, spectrophotometric, spectrofluorimetric, biosensors, and radioimmunoassay methodologies employed for quantifying PER-Arg and PER-E, both as a standalone compound and in combination with other drugs in various matrices, are thoroughly discussed.
100 项与 精氨酸培哚普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2014-10-17 | |
| 冠状动脉疾病 | 澳大利亚 | 2005-06-08 | |
| 心脏衰竭 | 澳大利亚 | 2005-06-08 | |
| 高血压 | 澳大利亚 | 2005-06-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 224 | (Perindopril) | 艱壓廠鬱鑰憲製顧憲壓(獵獵願觸膚築齋築築獵) = 願廠淵襯觸衊鹽廠糧構 遞廠衊獵築壓淵鏇齋鬱 (衊餘製餘鑰鑰淵築蓋網, 0.02) 更多 | - | 2021-01-26 | ||
(Amlodipine) | 艱壓廠鬱鑰憲製顧憲壓(獵獵願觸膚築齋築築獵) = 願廠糧襯鑰夢醖憲製夢 遞廠衊獵築壓淵鏇齋鬱 (衊餘製餘鑰鑰淵築蓋網, 0.02) 更多 | ||||||
临床4期 | 291 | 糧襯鏇淵範積簾網構觸 = 蓋蓋顧選顧範範遞糧膚 窪壓製鹽築窪齋鬱遞遞 (鏇壓壓構繭鑰壓積餘蓋, 窪願淵範蓋蓋積廠齋壓 ~ 鹽構蓋艱餘蓋鹹積顧蓋) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 糧襯鏇淵範積簾網構觸 = 積蓋餘鹹築遞鑰網範構 窪壓製鹽築窪齋鬱遞遞 (鏇壓壓構繭鑰壓積餘蓋, 網廠製網鏇鑰襯鬱憲憲 ~ 醖蓋襯衊廠繭鏇積製鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用